“For the patients: making the unreasonable reasonable, one step at a time”
Being financially independent since age 13 and as a Wharton graduate (M&T program drop out due to work commitments), XQ has lived and worked in the US, China and Singapore, along with gaining extensive operating and investment experience in Europe. He is a seasoned global business leader/entrepreneur and a synergistic business partner to entrepreneurial scientists/innovators, with a track record in taking technologies from concept to commercial reality.
At a young age, XQ transformed Esco into a global life science and medical technologies group, growing shareholder value by 25% CAGR over 20 years (since 2000). He has developed multiple products and technologies from concept to profitable commercial reality, multiple patents and cumulative revenues over 1B dollars. Esco products are being sold in more than 100 countries, with more than 150,000 systems sold. Today, Esco is Singapore’s most global life sciences company, with operations (including R&D and manufacturing) across the US, Europe and China, and over 1300 employees.
As a former infertility patient, XQ has spearheaded Esco’s expansion into the fertility technologies / IVF market since 2012, which has grown into a major growth driver of the group and a world leader in embryo incubation and time lapse technologies today.
In 2014, XQ founded Esco Ventures and achieved a portfolio IRR of ~45% to date. He co-founded Carmentix in 2015, with the mission of addressing the early prediction of preterm birth, in order to enable prevention. Today, Carmentix has achieved stellar clinical results which has been published in the American Journal of Obstetrics & Gynecology MFM.
XQ launched Esco Ventures X in 2018, Asia’s springboard for biotech startups operating across Singapore and Boston. He remade himself as a biotech company builder and co-founded Esco Venture’s current flagship company, Carmine Therapeutics, with Harvey Lodish, Minh Le and Jiahai Shi in 2019. Headquartered in Cambridge MA, Carmine Therapeutics is pioneering a new class of redosable gene therapies based on red blood cell extracellular vesicles.
XQ is also passionate in developing the biotech ecosystem in Singapore and Asia. In 2015, Esco Ventures launched one of the first wet lab incubators, followed by the Morphosis venture fellowship in 2018 (talent development), and the PLATINUM grant in 2020 (pre seed grant funding to academic labs).